Plain-English translation of NCT06515314 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing a new treatment called HRYZ-T102, which uses your own immune cells that have been specially engineered in a laboratory to recognize and attack liver cancer cells. The study will enroll 12 to 24 patients and follow them for 24 months to see if this medication is safe and how well it works.
Many patients with advanced liver cancer have limited treatment options after their first treatments stop working. This trial exists to explore whether training immune cells to specifically target cancer cells could offer a new way to fight this disease.
You likely qualify if…
You likely don't qualify if…
First, you will undergo a procedure called lymphocytapheresis, where doctors collect some of your white blood cells through a special machine that works similarly to dialysis. Your cells are then sent to the laboratory to be engineered, a process that takes several weeks. Once ready, you will receive a single injection of the engineered cells back into your body. You will then be followed closely for 24 months with regular clinic visits and tests to monitor your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Shanghai Ruiliyuan Biotechnology Co., Ltd.
Enrollment target
~12 participants
Started
October 2024
Primary completion
August 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wenjin Huang
Study Principal Investigator
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.